While it is true that the Regen BioPharma (OTCMKTS:RGBP) stock was trading within a range on Monday, it should not be ignored that the company was actually in the news and it may be a good idea to look into it a bit more closely.
Trading Data
On Monday, RGBP stock ended flat at $0.0102 with more than 73.57 million shares traded, compared to its average volume of 43.79 million shares. The stock moved within a range of $0.0096 – 0.0119 after opening trading at $0.0115.
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
After all, the stock may break out eventually and hence, it may be crucial to be abreast of all the facts. Yesterday, the company made a joint statement along with Oncology Pharma Inc in which it was noted that the two companies seek to collaborate on fast tracking the development of therapeutics meant for treating pancreatic cancer patents.
The two companies are going to be involved in deploying the ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES that have been developed by Regen. It goes without saying that it was a significant development for the company and one that could propel the company into new highs in the long term. The collaboration with a seasoned operator like Oncology Pharma is also an important thing. It now remains to be seen if the stock can manage to go on a move over the course of the coming days as more and more investors learn of the news.
Key Quote
“I am very excited to get our newly patented modified mRNA technology advanced to the point whereby an IND can be submitted to the FDA,” says David Koos, CEO and Chairman of Regen. “I expect that once our experimental protocols are set up, the path to a cleared IND from the FDA will be straightforward.”
Technical Data
RGBP stock is trading below the 20-Day and 50-Day Moving averages of $0.0110 and $0.0127 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0209.
